Sepantronium - CAS 781661-94-7
Catalog number: B0084-286781
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H19BrN4O3
Molecular Weight:
443.29386
COA:
Inquire
Targets:
Survivin
Description:
Sepantronium, also known as YM-155, is a small-molecule proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.
Purity:
>98%
Appearance:
Light yellow to yellow solid
Synonyms:
YM-155
MSDS:
Inquire
Application:
For research used only
InChIKey:
QBIYUDDJPRGKNJ-UHFFFAOYSA-M
InChI:
InChI=1S/C20H19N4O3.BrH/c1-13-23(9-10-27-2)17-18(24(13)12-14-11-21-7-8-22-14)20(26)16-6-4-3-5-15(16)19(17)25;/h3-8,11H,9-10,12H2,1-2H3;1H/q+1;/p-1
Canonical SMILES:
CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]
Current Developer:
Astellas Pharma Inc.
1.A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
Papadopoulos KP1, Lopez-Jimenez J2, Smith SE3, Steinberg J4, Keating A4, Sasse C4, Jie F4, Thyss A5. Leuk Lymphoma. 2016 Feb 9:1-8. [Epub ahead of print]
This phase II study evaluated YM155, a novel small-molecule survivin suppressant, in combination with rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma (NHL) who failed or were not candidates for autologous stem cell transplant (ASCT). During 14-day cycles, 41 patients received YM155 (5mg/m2/d) by continuous intravenous (IV) infusion for 168 hours (day 1-7), and rituximab (375mg/m2) IV on days 1 and 8 during cycles 1-4 and repeated for 4 cycles every 10 cycles. Forty patients (97.6%) had prior rituximab and 15 patients (36.6%) prior ASCT. Most frequent grade 3-4 adverse events were neutropenia (19.5%) and thrombocytopenia (12.2%). In the per-protocol set (n = 34), objective response rate was 50% and median progression-free survival 17.9 months. Median overall survival was not reached at study termination (median follow-up, 23 months). YM155 in combination with rituximab was tolerable with encouraging antitumor activity and durable responses in relapsed aggressive B-cell NHL patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Survivin Products


CAS 501698-03-9 GDP366

GDP366
(CAS: 501698-03-9)

GDP366 is a novel small molecule compound which potently and selectively inhibited the expression of both survivin and Op18. GDP366 induces cell growth inhibiti...

CAS 781661-94-7 Sepantronium

Sepantronium
(CAS: 781661-94-7)

Sepantronium, also known as YM-155, is a small-molecule proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits...

CAS 355406-09-6 YM-155 hydrochloride

YM-155 hydrochloride
(CAS: 355406-09-6)

YM155 is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM.

Chemical Structure

CAS 781661-94-7 Sepantronium

Quick Inquiry

Verification code

Featured Items